Glucagon-Like Peptide-1 and Psychiatric Disorder
Ayşe Şiva Acar1, Oytun Erbaş1,2
1ERBAS Institute of Experimental Medicine, Illinois, USA & Gebze, Turkey
2Department of Physiology, Medical Faculty of Demiroğlu Bilim University, Istanbul, Turkey
Keywords: Bipolar spectrum disorder, GLP-1, liraglutide, mood disorders, neuroprotection, obesity, schizophrenia
Abstract
GLP-1 (Glucagon-like peptide-1) receptor agonists have incretin, cardioprotective and neuroprotective effects. Liraglutide, a GLP-1 receptor agonist, is used to treat comorbid diseases such as obesity and diabetes through its incretin and cardioprotective effects. The therapeutic targets of Exenatide on neurodegenerative diseases have recently been concentrated, particularly after the discovery of GLP-1's neuroprotective effects. Mood disorders and metabolic comorbidities are the two groups of diseases that have the greatest global impact on mortality. There is also a significant correlation between patients with mood disorders and patients with obesity and T2DM (Type 2 diabetes mellitus), according to epidemiological data. GLP-1 receptor agonists are exceedingly being used to treat psychological disorders. According to the results of preclinical studies, Liraglutide can prevent cognitive function regression and develop normal functions. This condition suggests that GLP-1 receptor agonists could be useful in the treatment of psychiatric disorders in the future. This review examined the relationship between GLP-1 Receptor Agonists and Psychiatric diseases.
Cite this article as: Şiva Acar A, Erbaş O. Glucagon-Like Peptide-1 and Psychiatric Disorder. JEB Med Sci 2021;2(2):106-115.
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
The authors received no financial support for the research and/or authorship of this article.